ERBB2 and neoplasm: Both ECTM- and Δ16ECTM-phage vaccines were able to significantly reduce tumor growth rate (Figure 3C) and multiplicity (Figure 3D), and to induce antibodies toward HER2, in correlation with the conferred antitumor protection (Figure 3E).